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Cancer-associated cachexia (CAC) is a wasting
syndrome characterized by systemic inflammation,
body weight loss, atrophy of white adipose tissue
(WAT) and skeletal muscle. Limited therapeutic op-
tions are available and the underlying mechanisms
are poorly defined. Here we show that a phenotypic
switch from WAT to brown fat, a phenomenon
termed WAT browning, takes place in the initial
stages of CAC, before skeletal muscle atrophy.
WAT browning is associated with increased expres-
sion of uncoupling protein 1 (UCP1), which un-
couples mitochondrial respiration toward thermo-
genesis instead of ATP synthesis, leading to
increased lipid mobilization and energy expenditure
in cachectic mice. Chronic inflammation and the
cytokine interleukin-6 increase UCP1 expression in
WAT, and treatments that reduce inflammation or
b-adrenergic blockade reduce WAT browning and
ameliorate the severity of cachexia. Importantly,
UCP1 staining is observed in WAT from CAC
patients. Thus, inhibition of WAT browning repre-
sents a promising approach to ameliorate cachexia
in cancer patients.
INTRODUCTION
Cancer-associated cachexia (CAC) is a paraneoplastic syn-
drome characterized by systemic inflammation, body weight
loss, atrophy of adipose tissue, and skeletal muscle wasting.
CAC is observed in a majority of cancer patients with advanced
disease (Fearon et al., 2012; Tisdale, 2002). In addition to cancer
patients, cachexia is typically seen at the end stage of various
other morbidities, including infectious diseases, such as AIDSCell Meand tuberculosis, or chronic conditions, such as congestive
heart failure, chronic obstructive lung disease, andmultiple scle-
rosis (Tisdale, 2009). No effective treatment is currently available
for cachexia, which is responsible for approximately 20%of total
deaths in cancer patients (Fearon et al., 2013). Therefore, new
therapeutic targets for cachexia prevention and treatment are
urgently needed.
Metabolic dysfunction and increased metabolic rate have
been proposed as causative for CAC (Blum et al., 2011), but
the underlying mechanisms are at present poorly characterized
(Tisdale, 2009). Activation of thermogenesis in the interscapular
brown adipose tissue (BAT) has been observed in a syngeneic
mouse tumor transplant model and suggested to contribute to
the hypermetabolic state of cachexia (Tsoli et al., 2012). White
adipose tissue (WAT) and BAT usually perform opposite physio-
logical functions, with WAT responsible for energy accumulation
in intracellular lipid droplets and BAT responsible for its dissipa-
tion as heat (Cannon and Nedergaard, 2004). Interscapular BAT
is not the only thermogenic organ in mice and humans. Brown
adipocytes can also be induced within WAT depots, a phenom-
enon termedWAT browning (Wu et al., 2013; Young et al., 1984).
Brown adipocytes induced in WAT, also known as ‘‘beige’’ or
‘‘brite’’ cells (Harms and Seale, 2013), are derived from a pre-
cursor population distinct from both mature white and brown
adipocytes (Wang et al., 2013). Several mechanisms have
been proposed for WAT browning (Villarroya and Vidal-Puig,
2013), including prolonged cold exposure (Loncar et al., 1986),
adrenergic activation (Cao et al., 2011), the myokine Irisin (Bos-
tro¨m et al., 2012), and the prostaglandin synthesis enzyme cyclo-
oxygenase (COX) 2 (Vegiopoulos et al., 2010). WAT browning is
responsible for a significant increase in total energy expenditure
(Shabalina et al., 2013), and stimulation of browning has thera-
peutic potential to promote body fat reduction (Yoneshiro
et al., 2013).
WAT atrophy represents one of the hallmarks of cachexia and
is caused by b-adrenergic activation and/or inflammatory cyto-
kine-induced lipolysis (Das et al., 2011; Fearon et al., 2012).
Notably, b-adrenergic stimulation is also responsible for WATtabolism 20, 433–447, September 2, 2014 ª2014 Elsevier Inc. 433
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more, several activators of interscapular BAT also promote
WAT browning (Wu et al., 2013). Since the b-adrenergic pathway
is active during cachexia, and increased thermogenesis in BAT
has been observed in cachectic mice (Tsoli et al., 2012), we
set out to investigate whether WAT browning occurs and to
analyze its impact on CAC pathophysiology. WAT browning
was observed in different model systems, indicating that it is a
consistent feature of cachexia. WAT browning during CAC
contributed to the systemic increase in energy expenditure and
promoted the wasting syndrome. Decreasing WAT browning
by silencing tumor production of interleukin-6 (IL-6) or pharma-
cological approaches employing an anti-IL-6 monoclonal anti-
body, a b3-adrenergic receptor antagonist, or the nonsteroidal
anti-inflammatory drug sulindac ameliorated the severity of
cachexia. Importantly, browning of adipose tissue was observed
in samples from cancer cachexia patients, thus underlining the
translational value of our findings.
RESULTS
Browning of Subcutaneous WAT Is a Consistent Finding
in Mouse Models of CAC
A systematic morphological analysis of WAT depots in different
mousemodels of CAC led to the identification of a robust pheno-
typic switch from white to brown fat in subcutaneous WAT
of cachectic mice. Genetically engineered mouse models
(GEMMs) of lung and pancreatic cancer, Kras-lung cancer
GEMM (Puyol et al., 2010), and Kras-pancreatic cancer GEMM
(Hingorani et al., 2005), respectively, at the age of 6–8 months
displayed a loss of more than 15% of total body weight, when
compared to littermate controls (Figure 1A). At necropsy,
GEMMs of cancer exhibited massive fat atrophy, as evidenced
by complete loss of gonadalWAT (Figure 1B). Histological exam-
ination of subcutaneous inguinal and axillary WAT, also termed
anterior subcutaneous WAT (Walde´n et al., 2012), revealed the
presence of abundant islets composed of small adipocytes
with big nuclei, multilocular cytoplasm, and positive staining
for the uncoupling protein-1 (UCP1) (Figures 1C and 1D). WAT
browning was also evident in a third GEMM of CAC; K5-SOS
mice with skin tumors (Sibilia et al., 2000) displayed increased
UCP1 staining in subcutaneous WAT as well as in the residual
gonadal WAT (Figure S1A, available online). Next, we investi-
gated WAT morphology and UCP1 protein in a chemical model
of liver carcinogenesis; 19 months after injection of the carcin-
ogen diethylnitrosamine (DEN), 50% of mice became cachectic
(Figure S1B) and exhibited morphological evidence of subcu-
taneous WAT browning (Figure 1E).
WAT browning was also observed in murine syngeneic graft
models. At 2 weeks after injection of B16 melanoma cells or
Lewis lung carcinoma (LLC) cells, mice lost 25% of gonadal
WATmass, while total body weight was reduced only in the graft
model with B16 cells (Figures S1C and S1D). Although the
severity of cachexia in the syngeneic graft models was milder
compared to cachexia observed in the tumor GEMMs, subcu-
taneousWAT frommice in both graft models displayed evidence
of WAT browning, as shown by increased UCP1 staining and
decreased lipid droplet size (Figures 1F, 1G, S1E, and S1F).
Lastly, WAT morphology was investigated in a xenogeneic graft434 Cell Metabolism 20, 433–447, September 2, 2014 ª2014 Elseviemodel of human cancer. Two tumor samples, Panc34 and
Panc42, were obtained from distinct pancreatic cancer patients
and implanted subcutaneously in immunocompromised SCID
mice with a defective lymphocyte response. At 3 months after
implantation, mice from both groups grew xenograft tumors of
similar size, lost more than 15% of total body weight, and dis-
played evidence of browning of subcutaneous WAT (Figures
S1G–S1I). These data obtained in very diverse experimental
models of cancer show that WAT browning represents a consis-
tent finding in CAC.
WAT Browning Is an Early Event in the Pathophysiology
of CAC
To investigate the kinetics of WAT browning and to determine
whether it contributes to the wasting process in CAC, we
focused on the K5-SOS mouse model of skin tumors, in which
the temporal development of cachexia is rapid and reproducible.
At 5 weeks of age, K5-SOSmice did not show evidence of loss of
total body weight or skeletal muscle mass, but they exhibited
increased spleen weight and a 50% reduction in gonadal WAT
mass (precachectic mice) (Figures 2A and 2B). However, un-
equivocal signs of cachexia were evident in K5-SOS mice at
7weeks of age,with significant total bodyweight loss (Figure 2A),
anemia (Figures S2A and S2B), nearly complete atrophy of
gonadalWAT, and a 50% reduction in skeletal musclemass (Fig-
ures 2B and S2C–S2E). At the molecular level, changes
described in skeletal muscle of cachectic mice (Zhou et al.,
2010), such as increased nuclear staining of phospho-SMAD2,
increased expression of the cell-cycle inhibitor p21, the proapo-
ptotic gene Bax, and the proinflammatory cytokine interleukin-6
(IL-6), were observed in skeletal muscle of K5-SOSmice (Figures
S2F and S2G). Also, increased activation of interscapular BAT
was observed in cachectic mice (Figure S2H).
Remarkably, WAT browning was already detectable in preca-
chectic mice and increased as cachexia developed (Figures 2C
and 2D). Ucp1mRNA was upregulated in both inguinal and axil-
lary WAT from cachectic K5-SOS mice, along with established
molecular markers of browning, such as Pgc1a, Pparg, Cidea,
and Prdm16 (Figures 2E and 2F). Browning of subcutaneous
WAT in cachectic mice was associated with increased mito-
chondrial content and oxygen consumption (Figures 2G and
2H). Similarly, total levels of mitochondrial protein NDUFS1
were increased in subcutaneousWAT of cachectic mice (Figures
S2I and S2J). Analysis of established expression signatures for
beige-selective and brown-selective genes (Wu et al., 2012)
showed a consistent increase of brown-selective markers in
subcutaneous WAT of cachectic mice (Figures S3A and S3B).
Furthermore, the percentage of proliferating cells was doubled
in subcutaneous WAT of cachectic mice, when compared to
controls (Figure S3C). Recent studies have shown that newly
induced beige/brite adipocytes, induced in WAT by cold expo-
sure or adrenergic b3-agonist treatment, arise by recruitment
and de novo differentiation of progenitor cells (Wang et al.,
2013). To better characterize the identity of proliferating cells in
WAT of cachectic mice, we performed costaining experiments
with established markers of adipocyte progenitors (Lee et al.,
2012; Tang et al., 2011) and identified proliferating PDGFRa-
positive cells, but not PDGFRb or PPARg cells (Figure S3D).
These data show that WAT browning represents an early eventr Inc.
Figure 1. Browning of WAT Is a Consistent Finding in Mouse Models of CAC
(A) Total body weight in Kras-pancreatic cancer GEMM, Kras-lung cancer GEMM, and corresponding littermate controls (6–8 months old, nR 6 per genotype).
(B) Representative macroscopic pictures of control mice and Kras-pancreatic cancer GEMM at autopsy. The arrowheads point to normal gonadal WAT in control
mice. In the GEMM of pancreatic cancer (arrow), gonadal WAT is almost completely absent, and the gonads are visible (asterisk).
(C and D) Representative images of hematoxylin and eosin (H&E) (C) and UCP1 immunohistochemical (IHC) (D) staining of subcutaneous WAT in mice from (A).
(E) Representative images of UCP1 IHC staining of axillary WAT in mice in the DEN-induced model of liver tumors (16–18 months old, n = 3 per condition).
(F and G) Quantification of brown area extension (F) and lipid droplet size (G) in axillary WAT frommice in the graft model with melanoma B16 cells (12 weeks old,
nR 6 per condition).
Data are presented as mean ± SEM (*p < 0.05).
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wasting. Moreover, WAT browning is associated with increased
energy consumption in subcutaneous WAT and is characterized
by activation of brown-selective genes and proliferation of
PDGFRa progenitor cells.Cell MeIncreased Systemic Energy Expenditure in Cachectic
K5-SOS Mice
To determine the impact of WAT browning on systemic meta-
bolism, we studied metabolic parameters in tumor-bearing
mice. Precachectic K5-SOS mice (5 weeks old) were placed intabolism 20, 433–447, September 2, 2014 ª2014 Elsevier Inc. 435
Figure 2. Browning of WAT Is an Early Event in the Pathophysiology of CAC
(A and B) Changes in total body (A) and organ (B) weight in 5-week-old (precachectic) and 7-week-old (cachectic) K5-SOS mice and littermate controls.
(C and D) Representative images of UCP1 IHC staining (C) and western blot analysis (D) of axillary WAT.
(E and F) Gene expression analysis of browning markers in inguinal (E) and axillary (F) WAT.
(G and H) Analysis of mitochondrial DNA content (G) and oxygen consumption rate (OCR) (H) in isolated inguinal and axillary WAT.
For all panels, nR 8 per genotype and per group. Data are presented as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001).
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WAT Browning in Cancer-Associated Cachexiametabolic cages and examined for 2 weeks. Energy expenditure
(EE) progressively increased in K5-SOS mice over this time in
both diurnal and nocturnal periods and reached significantly
increased values during the last 3 days, when mice were overtly
cachectic (Figures 3A and 3B). Respiratory exchange ratios
(RERs) were reduced in K5-SOS mice, highlighting the impor-
tance of lipids as the primary fuel source in cachectic mice (Fig-
ures 3C and 3D). Food intake was increased in cachectic mice
(Figure 3E), yet feeding a high-fat diet did not prevent loss of total
body weight or tissue atrophy (Figures S4A and S4B). Notably,
energy expenditure was increased in cachectic mice despite
reduced locomotor activity (Figure 3F).
Increased glucose recycling via lactate, a metabolic pathway
termed the Cori cycle, has been described in cachectic cancer
patients and suggested to play a causal role in the increased
energy expenditure (Holroyde et al., 1984; Tisdale, 2009). To
analyze a possible contribution of the Cori cycle to the cachectic
phenotype observed in K5-SOSmice, the levels of substrates for
gluconeogenesis were measured by NMR in plasma and tissue
extracts from liver and skeletal muscle. Although significantly
increased levels of alanine (plasma and liver) and pyruvate (liver)
were detected in cachectic mice, which may suggest enhanced
Cori cycle activity, these increases were not accompanied by a
corresponding increase in lactate levels, which remained un-
changed and of much higher magnitude (Figures S4C–S4E).
Furthermore, expression levels of key enzymes, transporters,
and transcription factors involved in lactate metabolism (Sum-
mermatter et al., 2013) were similar in liver and skeletal muscle
fromK5-SOS and control mice (Figures S4F and S4G), indicating
that the Cori cycle is not significantly active in this cachectic
model.
Atrophy of gonadal WAT in K5-SOS mice was associated with
increased triglyceride hydrolase activity due to increased activity
of adipose triglyceride lipase (ATGL) and hormone-sensitive
lipase (HSL), as confirmed by the reduction in fatty acid and
glycerol release from gonadal WAT explants after addition of
the respective lipase inhibitor (Figures 3G and 3H). Interestingly,
while inhibition of ATGL and HSL led to a reduction greater than
85% in fatty acid and glycerol release from gonadal WAT of
control mice (86% and 97% reduction, respectively), the fold
reduction after lipase inhibitors was considerably less for K5-
SOS mice (60% and 67% reduction, respectively), indicating
that higher doses of inhibitors are required to counteract lipolysis
during cachexia. Alternatively, other yet-unidentified lipases
may become active and contribute to triacylglycerol hydrolysis
and WAT loss in cachexia. Increased lipolysis was also evident
in inguinal and axillary WAT (Figure 3I) due to pronounced
overexpression of adipose ATGL, HSL, and phospho-HSL (Fig-
ure 3J). The increase in lipidmobilization and energy expenditure
despite decreased locomotor activity suggests that WAT
browning, together with enhanced thermogenesis in interscapu-
lar BAT, contributes to excessive substrate oxidation and
wasting in CAC.
Role of Inflammation in the Pathophysiology of WAT
Browning in Cachexia
Although it is established that WAT browning enhances thermo-
genesis (Cousin et al., 1992), rectal temperature was reduced in
7-week-old cachectic K5-SOSmice housed at standard temper-Cell Meatures (23C) (Figure S5A). To evaluate whether WAT browning
represents a defense mechanism against lower body tempera-
ture (Wu et al., 2013), mice were kept at thermoneutrality
(30C) starting at 4 weeks of age. Housing mice at thermoneu-
trality for 1 month did not affect the loss of WAT and skeletal
muscle mass and did not rescue the reduction in body tempera-
ture or the WAT browning phenotype (Figures S5B–S5E). These
data show that WAT browning in cachectic mice is independent
of environmental thermal stimuli.
Searching for a common cause of WAT browning in all
analyzedmodels of CAC, we reasoned that chronic inflammation
would be a good candidate, since it is a hallmark of both clinical
(Blum et al., 2011) and experimental CAC (Fearon et al., 2012). In
order to define the potential role of inflammation in the pathogen-
esis of the WAT browning phenotype, we examined inflamma-
tion-induced signaling pathways in WAT of mice with the
K5-SOS, Kras-pancreatic cancer GEMM, and colon carcinoma
C26 syngeneic tumors (Tsoli et al., 2012). In all three models,
STAT3 was activated, and phosphorylation of the MAPK p38
was increased in WAT of K5-SOS and C26 mice (Figures S6A–
S6C). Increased expression of Socs3, downstream of STAT3,
and Cox1, indicative of enhanced prostaglandin signaling, was
observed (Figures S6D and S6E). Furthermore, systemic chronic
inflammation was documented by leukocytosis with increased
neutrophil/lymphocyte ratio (Figures S6F and S6G) and fibrosis
of subcutaneous WAT and liver (Figures S6H–S6K). Notably,
cachectic mice displayed increased IL-6 levels in blood
(Figure S6L).
IL-6 is a proinflammatory cytokinewith amajor role in cachexia
pathophysiology (Fearon et al., 2012). To further delineate the
role of IL-6 in promoting WAT browning, we employed C26
carcinoma cells, which are IL-6 proficient, as well as a C26 tumor
variant that lacks IL-6. Although the syngeneic tumor from IL-6-
proficient C26 cells was smaller compared to the tumor from
IL-6-deficient C26 cells (Figure 4A), only mice injected with
IL-6-proficient C26 cells rapidly lost body weight and became
cachectic (Figures 4B and 4C). Likewise, UCP1 protein content
was high only in subcutaneous WAT of mice implanted with
IL-6-proficient C26 tumors (Figure 4D). To confirm the role of
IL-6 in causing cachexia in the C26 colon cancer model, we
blocked IL-6 expression in IL-6-proficient C26 cells by stable
incorporation of an shRNA targeting IL-6. Preventing IL-6 release
by C26 tumors completely rescued the cachectic phenotype
(Figures 4E and 4F). Notably, silencing IL-6 in C26 tumors also
blocked the increased UCP1 protein expression in subcutane-
ous adipose tissue (Figure 4G). In addition, the increased mito-
chondrial respiratory function observed in axillary WAT from
mice implanted with IL-6-proficient C26 cells was partially
normalized after IL-6 silencing (Figure 4H).
To further address the role of IL-6 inWAT browning, an anti-IL-
6 blocking antibody was used. Anti-IL-6 treatment was started in
K5-SOSmice at 5 weeks of age, when a severe reduction in total
fat mass was documented by dual-energy X-ray absorptiometry
(DXA) analysis (Figure S6M). Treatment for 2 weeks with anti-IL-6
monoclonal antibody prevented the further reduction of total
body fat and reduced UCP1 protein levels in subcutaneous
WAT (Figures 4I and 4J). Despite the beneficial effect on WAT
atrophy, total body loss was not affected by anti-IL-6 treatment
(Figure S6N). The partial effect could be due to the inability oftabolism 20, 433–447, September 2, 2014 ª2014 Elsevier Inc. 437
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iments, the severity of cachexia was investigated in IL-6 receptor
knockout (IL-6-R-KO) mice. At 2 weeks after implantation of B16
melanomas, WAT atrophy was significantly reduced in mutant
mice, although the protection against total body weight loss
was small and did not reach statistical significance (Figures 4K
and 4L). Importantly, UCP1 protein levels in subcutaneous
WAT from IL-6-R-KO mice implanted with B16 melanoma cells
were drastically reduced when compared to control mice (Fig-
ure 4M). Combined with the functional evidence for reversal of
browning in the IL-6 knockdown C26 tumor model, these data
establish that IL-6 signaling plays an important role in the WAT
browning phenotype observed in mouse models of cachexia.
Role of b-Adrenergic Activation in the Pathogenesis of
WAT Browning in Cachectic Mice
It has recently been reported that IL-6 determines alternative
activation of macrophages (Mauer et al., 2014). Interestingly,
alternatively activated macrophages sustain adaptive thermo-
genesis in BAT through enhanced recruitment of b-adrenergic
fibers (Nguyen et al., 2011). Macrophage infiltration was evident
in subcutaneous WAT of mice in the syngeneic graft model with
IL-6-proficient C26 cells, as well as in other models of cachexia,
including K5-SOS mice and mice in the xenogeneic transplant
model with human pancreatic cancer (Figure S7A and data not
shown). Gene expression analysis of axillary WAT in K5-SOS
mice showed increased levels of markers of the alternatively
activated M2 macrophages (IL4 and Arg1), while levels of the
M1 marker TNFa were unchanged (Figure S7B). Positive immu-
nohistochemical staining for the rate-limiting enzyme of cate-
cholamine synthesis, tyrosine hydroxylase (TH), confirmed
b-adrenergic activation in WAT of cachectic mice (Figure S7C).
To determine the role of adrenergic innervation in the induction
of the thermogenic program in cachectic mice, we tested
whether bilateral surgical denervation of BAT would affect the
increased UCP1 protein levels observed in this tissue in K5-
SOSmice. At 1 week after surgery, BAT from denervated control
mice appeared pale, displayed adipocytes of bigger dimensions
with less vacuolization of the cytoplasm, and showed a drastic
reduction in UCP1 protein levels (Figures 5A–5D). Interestingly,
in K5-SOS mice, although BAT denervation was also effective
in decreasing UCP1 levels, residual protein levels were higher
than those in denervated control mice (Figures 5A–5D). These
data suggest that the presence of an intact adrenergic innerva-
tion is essential for the complete induction of the thermogenicFigure 3. Increased Systemic Energy Expenditure and Lipid Mobilizati
Precachectic K5-SOS mice and littermate controls (5 weeks old) were housed in
3 days of measurement are shown, a time point at which K5-SOS mice were ove
(A) Energy expenditure (EE) at each time point.
(B) Average EE over the last 3 days
(C) Respiratory exchange ratio (RER) at each time point.
(D) Average RER over the last 3 days.
(E) Food intake.
(F) Overall motility.
(G and H) Fatty acid (FA) (G) and glycerol (H) release from gonadal WAT under b
inhibitor (Hi76-0079).
(I) In vitro triglyceride hydrolase activity of lysates from gonadal, inguinal, and ax
(J) Western blot analysis of ATGL, phospho-HSL, and HSL protein levels in axilla
For all panels, nR 6 per genotype. Data are presented as mean ± SEM (*p < 0.0
Cell Meprogram in BAT of cachectic mice. However, even in the
absence of innervation, adrenergic-independent mechanisms
still determine a partial increase of UCP1 protein levels.
We next tested in vitro whether IL-6 was able to directly
increase Ucp1 levels in adipocytes. We used 3T3-L1 pre-white
adipocytes retrovirally transduced with Cebp/b (Ortega-Molina
et al., 2012), as a model of pre-brown adipocytes, as well as pri-
mary adipocytes from inguinal WAT. Treatment with the cyclic
AMP inducer Forskolin increased Ucp1 expression levels by 8-
fold and 30-fold in the cell line and in primary adipocytes, respec-
tively (Figures S7D and S7E). Although less robust, a statistically
significant increase in Ucp1 mRNA levels was observed after
treatment of both cell models with recombinant murine IL-6 (Fig-
uresS7DandS7E), thusprovidingevidence fora small butdistinct
effect of the cytokine upon Ucp1 expression in adipocytes.
These data show that chronic inflammation together with
b-adrenergic activation functionally cooperate in the pathogen-
esis of increased adipose tissue thermogenesis in cachexia.
b3-Adrenergic Receptor Blockade and Anti-
Inflammatory Treatment Ameliorate Cachexia
Adrenergic control of thermogenesis in adipose tissue is medi-
ated mainly by b3-adrenergic receptors (Cao et al., 2011). To
investigate the potential to prevent cachexia, treatment with
the selective b3-adrenergic receptor (b3-AR) antagonist was
started in mice after weaning, at 3 weeks of age, when no sign
of cachexia was apparent in K5-SOS mice. Treating mice for
4 weeks with the selective b3-AR antagonist ameliorated
cachexia and decreased UCP1 levels in subcutaneous WAT
(Figures 6A–6C). While inhibition of b3-AR did not significantly
reduce Ucp1 mRNA expression levels in subcutaneous WAT of
control mice, the treatment was effective in reducing Ucp1
expression in K5-SOS mice (Figure 6C). Similarly, multilocular
areas were reduced in subcutaneous WAT of K5-SOS mice
treated with the selective b3-AR antagonist, when compared to
vehicle-treated cachectic mice (Figure 6D).
The increased chronic inflammation observed in cachectic
mice prompted us to treat K5-SOS mice with the nonselective
COX1/2 inhibitor, nonsteroidal anti-inflammatory drug sulindac.
Similarly to the experimental design with the b3-AR antagonist,
the preventive potential of sulindac was tested starting the treat-
ment at 3 weeks of age. Treating K5-SOS mice for 4 weeks with
sulindac was very effective in ameliorating the severity of
cachexia, along with a reduction of browning in subcutaneous
WAT (Figures 6E–6H). Similarly to what was observed with theon in Cachectic Mice
dividually in metabolic cages and recorded during 2 weeks. Results of the last
rtly cachectic.
asal conditions and after treatment with ATGL inhibitor (Atglistatin) plus HSL
illary WAT.
ry WAT.
5; **p < 0.01; ***p < 0.001).
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Figure 5. Reduced UCP1 Protein Levels in
Interscapular BAT after BAT Denervation in
Cachectic Mice
(A) Representative macroscopic pictures of BAT
from 5-week-old K5-SOS mice and littermate
controls, 1 week after bilateral BAT denervation
surgery or sham operation.
(B) Representative images of H&E staining of BAT.
(C and D) Western blot analysis of UCP1 protein
levels (C) and corresponding quantification
(s, sham operated; d, BAT denervation) (D).
Data are presented as mean ± SEM; n = 3 per ge-
notype and per condition.
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expression levels in cachectic mice (Figure 6G). Notably, a
reduction in UCP1 protein levels in WAT of sulindac-treated
mice was already detected after 1 week of treatment (FiguresFigure 4. Role of Inflammation and IL-6 in the Pathophysiology of WAT Browning in Cachexia
(A) Tumor weight in mice in the graft model with C26 colon cancer cells proficient or deficient for IL-6 (12 w
(B and C) Changes in body (B) and organ (C) weight of mice in (A).
(D) Western blot analysis of UCP1 protein levels in axillary WAT of mice in (A).
(E) Plasma IL-6 levels in mice in the graft model with C26/IL-6 proficient cells with stable incorporation o
condition).
(F) Measurement of body weight of mice in (E).
(G) Representative images of UCP1 IHC staining of axillary WAT of mice in (E).
(H) Analysis of oxygen consumption rate in isolated axillary WAT of mice in (E).
(I) Measurement of total WATmass by DXA scan in K5-SOSmice before and after treatment with rat anti-mous
old; post: 7 weeks old; n = 5 per condition and per time point).
(J) Representative images of H&E staining of axillary WAT of mice in (I).
(K and L) Changes in total body (K) and organ (L) weight in IL-6-receptor KO mice and littermate controls, in
old, n = 6 per genotype).
(M) Western blot analysis of UCP1 protein levels in axillary WAT of mice in (K).
Data are presented as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001).
Cell Metabolism 20, 433–447, SS7F and S7G), a time point when amelio-
ration of cachexia was not yet seen, thus
showing that the reduction ofWAT brown-
ing is an early effect of sulindac treatment.
These experiments show that preven-
tive treatments are effective in amelio-
rating the severity of cancer cachexia
and that nonsteroidal anti-inflammatory
drugs are more potent than b3-AR
blockade.
UCP1 Expression in Adipose Tissue
from Cancer Cachexia Patients
Next, we explored the translational value
of our findings and obtained eight sam-
ples of adipose tissue from cachectic
cancer patients (Figure 7A). Despite the
different anatomical location of the
various adipose samples and regardless
of the site of origin of the primary tumor,
adipose tissue from cachectic patients
exhibited morphologic features of atro-
phy: individual fat cells were reduced in
size, had lost much of their cytoplasm,
and showed a rounded or epithelioidappearance (Sternberg, 2006) (Figure 7B). In contrast, intestinal
adipose tissue from patients with colon cancer, but no cachexia,
appeared normal, with big adipocytes and small nuclei and
being rich in lipids (Figure 7B). Importantly, a positive UCP1eeks old, n = 7 per condition).
f shIL-6 or control vector (12 weeks old, n = 6 per
e IL-6monoclonal antibody or vehicle (pre: 5 weeks
the graft model with melanoma B16 cells (10 weeks
eptember 2, 2014 ª2014 Elsevier Inc. 441
Figure 6. Amelioration of Cachexia by b3-Adrenergic Receptor Antagonism or Anti-Inflammatory Treatment
(A andB) Changes in total bodyweight (A) and organweight (B) in K5-SOSmice treatedwith b3-AR antagonist or vehicle (7 weeks old, nR 5 per genotype and per
condition).
(C) Analysis of Ucp1 gene expression levels in inguinal WAT in K5-SOS mice and littermate controls treated with b3-AR antagonist or vehicle.
(D) Representative images of H&E staining of axillary WAT in K5-SOS mice treated with b3-AR antagonist or vehicle.
(E and F) Changes in total body (E) and organ (F) weight in K5-SOS mice treated with sulindac or vehicle (7 weeks old, nR 5 per genotype and per condition).
(G) Analysis of Ucp1 gene expression levels in inguinal WAT in K5-SOS mice and littermate controls treated with sulindac or vehicle.
(H) Representative images of UCP1 IHC staining of axillary WAT in K5-SOS mice treated with sulindac or vehicle.
Data are presented as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001).
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eight samples analyzed (Figures 7A, 7C, and 7D). UCP1 staining
was not evident in the only one adipose tissue sample from the
pericardium observed, which may reflect differences in predis-
position toward activation of the thermogenic program in adi-442 Cell Metabolism 20, 433–447, September 2, 2014 ª2014 Elseviepose depots from anatomically distinct locations. Importantly,
UCP1 staining was observed in samples from intestinal adipose
tissue as well as fat surrounding the liver, kidney, and pancreas
(Figure 7A). In contrast, 0/20 samples of intestinal adipose tissue
from colon cancer patients without cachexia stained positive forr Inc.
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WAT Browning in Cancer-Associated CachexiaUCP1 (Figure 7C). These findings suggest that a common bio-
logical process may underlie adipocyte atrophy and UCP1
expression in cancer cachexia patients.
DISCUSSION
Cachexia is a lethal syndrome and a frequent complication in pa-
tients suffering from malignancy or chronic cardiac, pulmonary,
neurological, and infectious diseases. Originally conceived as a
state of ‘‘autocannibalism,’’ in which the organism depletes its
resources to provide nourishment to the tumor, cachexia is
now described as an inflammatory and neuroendocrine
response (Fearon et al., 2012). The severity of cachexia is
commonly unrelated to tumor size or stage, with small tumors
often responsible for severe wasting, as in the case of pancreatic
and lung cancer (Tisdale, 2009). A combination of reduced food
intake and abnormal metabolism characterizes the pathophysi-
ology of cachexia and determines the negative energy and
protein balance (Fearon et al., 2013). Unfortunately, improving
nutritional intake has limited therapeutic potential, and available
treatment options have no effect on the impaired metabolism
(Fearon et al., 2013). Therefore, the prognosis of cachexia is
currently very poor.
Here, we show that WAT browning represents an early and
systemic event in cachexia pathophysiology and contributes to
the increased energy expenditure and lipid mobilization.
Increased energy expenditure was associated with activation
of a thermogenic program in adipocytes characterized by
increased mitochondrial content and uncoupling activity. The
thermogenic activity was increased in interscapular BAT as
well as in subcutaneous WAT depots. Interestingly, in sub-
cutaneous WAT from cachectic mice there was a preferential
increase in expression levels of brown-selective over beige-
selective genes. This finding may seem unexpected, given the
reported increased expression of beige-selective genes in sub-
cutaneous WAT, when compared to interscapular BAT (Wu
et al., 2012). However, these gene signatures were established
in cell lines and validated in mice kept at ambient temperature,
when the thermogenic program is not active in subcutaneous
adipose depots. In fact, after activation of the thermogenic pro-
gram, both inguinal and axillary WAT from cachectic mice dis-
played a gene expression profile that more closely resembled
that of interscapular BAT. These data suggest that gene expres-
sion markers may be indicative of the activation state of the ad-
ipose tissue rather than its anatomical origin.
Activation of the thermogenic program in subcutaneous WAT
occurs as a response to lower temperatures (Cousin et al.,
1992). Although rectal temperature was decreased in cachectic
mice, this occurred at a later clinical stage, when the cachectic
phenotype was fully apparent. Several mechanisms account for
hypothermia in terminal cachectic mice, including decreased
insulating capacity due to loss of total WAT mass and
decreased heat production due to reduced locomotor activity.
Hypothermia in terminal mice may suggest that WAT browning
is a compensatory mechanism. In contrast, WAT browning took
place early in the progression of cachexia, preceding body
weight loss, muscle atrophy, and hypothermia. Remarkably,
different from cold-induced thermogenesis (Champigny and
Ricquier, 1990), increasing the ambient temperature to thermo-Cell Meneutrality (30C) did not suppress WAT browning in cachectic
mice.
The role of UCP1 in metabolism goes beyond thermoregula-
tion, as exemplified by diet- and b-adrenergic-induced thermo-
genesis, which are both active at thermoneutrality (Feldmann
et al., 2009). To date, WAT browning has been described as a
beneficial event, promoting weight loss and improving insulin
sensitivity in metabolic diseases (Bostro¨m et al., 2012; Feldmann
et al., 2009). However, here we show that WAT browning is dele-
terious in the context of cancer, contributing to energy dissipa-
tion and progression toward cachexia.
The pathophysiology of CAC is multifactorial, with many
different mediators cooperating at different stages of the disease
and in different cancer types (Fearon et al., 2012). We show that
systemic inflammation plays a critical role in the pathogenesis of
WAT browning. It is well known that inflammatory cytokines are
pyrogenic and change the thermoneutrality set-point in the
hypothalamus (Gordon, 2012). Experiments with IL-6 knockout
mice have shown that IL-6 is required for maximal induction of
UCP1 protein in subcutaneous fat depots in response to cold
exposure (Knudsen et al., 2014). Circulating levels of IL-6 were
increased in cachectic mice, and activation of IL-6 signaling
was documented in adipose depots by phosphorylation of
Stat3. The role of IL-6 was critical in the syngeneic graft model
with C26 cancer cells, where genetic blockade of IL-6 produc-
tion within the tumor prevented WAT browning and cachexia.
Moreover, WAT browning was reduced in IL-6-R-KO mice im-
planted with B16 melanoma cells. Despite these facts, it cannot
be excluded that other mediators in addition to IL-6 could stim-
ulateWAT browning in cachectic mice. In this regard, the protec-
tion observed in IL-6-R-KO mice implanted with B16 melanoma
cells was only partial, thus confirming that different mechanisms
other than IL-6 signaling contribute to cachexia.
The mechanism by which IL-6 induces WAT browning in
cachectic mice may involve alternative activation of macro-
phages (Mauer et al., 2014) and recruitment of b-adrenergic
fibers (Nguyen et al., 2011). Indeed, surgical ablation experi-
ments showed that the presence of an intact adrenergic innerva-
tion was essential for the complete induction of the thermogenic
program in BAT of cachectic mice. Although it was not possible
to perform surgical denervation of the subcutaneous WAT,
results of b3-AR blockade support a role for sympathetic inner-
vations in the pathogenesis of WAT browning in cachexia. In
addition, in vitro experiments showed a direct effect of IL-6 on
Ucp1 expression in isolated adipocytes. Even if the effect was
mild, chronically increased circulating IL-6 levels may induce
thermogenesis in adipose tissue, either alone or in combination
with other cytokines.
Circulating levels of IL-6 in patients with cancer correlate with
weight loss and reduced survival (Moses et al., 2009; Scott et al.,
1996). Blocking IL-6 in patients with CAC has been shown to
ameliorate several symptoms and signs of cachexia, like fatigue,
anorexia, and anemia, although it is ineffective upon loss of lean
mass (Bayliss et al., 2011). Results with monoclonal anti-IL-6
antibody in the K5-SOS mouse model recapitulate the partial
benefit observed in clinical trials and support the concept that
treatment of cachexia in cancer patients must start early (Fearon
et al., 2013). Due to the severity of commonly reported side
effects associated with anti-IL-6 therapy (Berti et al., 2013), ittabolism 20, 433–447, September 2, 2014 ª2014 Elsevier Inc. 443
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stage cancer patients. Alternative preventive strategies may
involve the use of b3-AR antagonists or, especially, nonsteroidal
anti-inflammatory drugs, which were effective in experimental
models. While both b3-AR blockade and sulindac treatment
significantly reduced WAT browning in cachectic mice, other
mechanisms could contribute to the therapeutic effect. Anti-
inflammatory treatment has been shown to reduce the acute
phase response and attenuate tumor progression in both pre-
clinical models and patients with metastatic tumors (Lundholm
et al., 1994). b3-AR blockade may protect against cachexia by
means of decreased lipolysis (Tisdale, 2009), although b-adren-
ergic activation is only one of several pathways to account for
increased lipolysis in CAC (Agustsson et al., 2007), and the pres-
ence of uniformly increased adrenergic activity in humans with
CAC remains to be documented (Klein and Wolfe, 1990).
The induction of brown adipocytes in WAT depots of humans
(Cypess et al., 2009; van Marken Lichtenbelt et al., 2009; Virta-
nen et al., 2009) has been shown recently to significantly affect
overall energy balance (Yoneshiro et al., 2013). Human brown
fat is composed of adipocytes similar to both classical interscap-
ular brown adipocytes (Cypess et al., 2013; Jespersen et al.,
2013; Lidell et al., 2013) and mouse white adipocytes converted
into brown (Sharp et al., 2012; Wu et al., 2012). Moreover, a
recent imaging study showed increased metabolic activity of
BAT in PET-CTs of cancer patients (Huang et al., 2011). We
have shown a switch from white to brown adipocytes in WAT
of mice with CAC. WAT browning, together with enhanced ther-
mogenesis in interscapular BAT, contributed to increased
systemic energy expenditure. Also, preventing WAT browning
by means of b3-AR antagonists or nonsteroidal anti-inflamma-
tory drugs ameliorated the wasting process. The observation
of increased UCP1 staining in adipose tissue from cachectic
cancer patients indicates that adipocyte atrophy may be associ-
ated with increased thermogenic activity in human cancer
cachexia. These data suggest that inhibition of WAT browning
represents a promising approach to ameliorate the severity of
cachexia in cancer patients.
EXPERIMENTAL PROCEDURES
Mice and Treatments
Mouse strains employed in this study have been previously described: Kras-
pancreatic cancer GEMM (Hingorani et al., 2005), Kras-lung cancer GEMM
(Puyol et al., 2010), K5-SOS mice (Sibilia et al., 2000), and IL-6-R-KO mice
(McFarland-Mancini et al., 2010). All studies were performed with littermates
of the same genetic background as controls. For the hepatic carcinogen
model, 15-day-old mice on a mixed C57BL/6/129 background were injected
intraperitoneally (i.p.) with 25 mg/kg DEN (Sigma-Aldrich). LLC cells (4 3
106) or B16 melanoma cells (23 106) were injected subcutaneously at dorsum
just below the neck in C57Bl/6 mice. C26 cells (1 3 106) were injected subcu-
taneously into the right flank of Balb/C3DBA1 hybrids. Mice used for injection
of tumor cells as well as control animals were 10–12 weeks of age. Xenograft
experiments were conducted in accordance with institutional guidelines of the
CNIO (Protocol PA34/2012). Chow (D8604, Harlan) and 45% high-fat diet
(D12451, Research Diets) were used in this study. For the thermoneutralityFigure 7. UCP1 Expression in Atrophic WAT from Cancer Cachexia Pa
(A) Origin of the primary tumor, anatomical location of the WAT, and UCP1 IHC s
(B and C) Representative images of H&E (B) and UCP1 IHC (C) staining of intest
(D) Magnification of UCP1 IHC staining in intestinal WAT from the cachectic pati
Cell Meexperiment, mice were introduced in the 30C environment 1 week after wean-
ing (4 weeks old) and housed with four mice per cage. Mice were acclimatized
for 1 week prior to monitoring. Rat anti-mouse IL-6 monoclonal antibody
(clone: MP5-20F3) was administered i.p. (five doses of 200 mg each, once
each 3 days). The b3-AR antagonist SR59230A (Sigma-Aldrich; 3 mg/kg
body weight per day) was administered through osmotic minipumps (Alzet).
Sulindac (Sigma-Aldrich) was administered in drinking water (180 mg/l). Full
methods are described in the Supplemental Experimental Procedures.
Human Tumor Samples
After patients’ informed consent had been obtained, excess tissues from
resected pancreatic carcinomas were xenografted at Hospital de Madrid -
Centro Integral Oncologico Clara Campal (FHM.06.10 ‘‘Establishment of
bank for tumors and healthy tissue in patients with cancer’’) under the indi-
cated Institutional Review Board approved protocols.
qRT-PCR/Immunoblot Analysis
Quantitative RT-PCR reactions were performed using GoTaq RT-qPCR
Master Mix (Promega) and Eppendorf fluorescence thermocyclers (Eppend-
dorf). The 2-DDCT method was used to quantify amplified fragments. Expres-
sion levels were normalized using two housekeeping genes (Actin and Gapdh).
Primer sequences will be provided on request. Immunoblot analysis was per-
formed using standard protocols and the following antibodies: mouse mono-
clonal anti-Actin (Sigma-Aldrich, A4700), rabbit polyclonal anti-ATGL (Cell
Signaling Technology, #2138), rabbit monoclonal anti-GAPDH (Cell Signaling
Technology, #2118), rabbit polyclonal anti-HSL (Cell Signaling Technology,
#4107), rabbit monoclonal anti-NDUFS1 (Abcam, ab157221), rabbit polyclonal
anti-p38a MAP-Kinase (Cell Signaling Technology, #9218), rabbit polyclonal
anti-Phospho-HSL (Cell Signaling Technology, #4126), rabbit polyclonal anti-
Phospho-p38a MAP-Kinase (Thr180/182; Cell Signaling Technology, #9211),
rabbit polyclonal anti-Phospho-STAT3 (Tyr705; Cell Signaling Technology,
#9131), rabbit polyclonal anti-STAT3 (Cell Signaling Technology, #9132),
rabbit polyclonal anti-UCP1 (Abcam, ab10983), mouse monoclonal anti-
Vinculin (Sigma-Aldrich, V9131).
Oxygen Consumption Rate
Oxygen consumption rates (OCRs) in homogenized adipose tissue depots
were analyzed by high-resolution respirometry (Oxygraph 2k, Oroboros Instru-
ments) using glycerol-3-phosphate as substrate. Electron transfer via complex
I in the respiratory chain was blocked by the addition of rotenone.
Indirect Calorimetric Studies
To measure O2 consumption, CO2 production, food intake, and spontaneous
motility, mice were housed in metabolic cages (LabMaster, TSE Systems
GmbH). Animals were familiarized to single housing for at least 3 days prior
to monitoring.
IL-6 Knockdown in C26 Tumors
IL-6 expression in C26 cells was knocked down with lentiviral constructs from
the MISSION shRNA Library (Sigma-Aldrich). Transduced cells were selected
with puromycin, single-cell clones were derived, and the clones were tested by
qPCR and ELISA for reduced IL-6 expression after in vitro IL-1b stimulation.
The C26 tumors with the stably integrated IL-6 shRNA construct or vector con-
trol were implanted into mice as outlined above.
Dual Energy X-Ray Absorptiometry Analysis
Whole-body fat mass density wasmeasured by a PIXImus2 scanner according
to the manufacturer’s protocol (Lunar Corporation).
Surgical Denervation
Mice (4 weeks old) underwent bilateral surgical denervation of the interscapu-
lar BAT under isoflurane anesthesia. A transverse incision was made justtients
tatus in the human cancer cachexia samples analyzed.
inal WAT from cancer patients with or without cachexia.
ent in (C).
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BAT outward from the surrounding muscle and white adipose tissue, the sym-
pathetic chains innervating the organ were exposed. Denervation was per-
formed by isolation and resection with scissors of the five branches of the
left and right intercostal nerve bundles, without disrupting the blood circula-
tion. In sham-operated mice, the sympathetic chains innervating BAT were
exposed but not resected. Mice were sacrificed 1 week after surgery.
Human Cancer Cachexia Slides
Paraffin sections of adipose tissue from cancer patients were obtained at
tumor biopsy or at necropsy. The samples were provided by the CNIO Tumor
Bank, CNIO, Madrid, and The Biobank of Hospital Clı´nic - IDIBAPS, Barcelona,
in accordance with the ethical guidelines of the Helsinki Declaration.
Statistical Analysis
Results are presented asmean ± SEM. p value was calculated using Student’s
t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.cmet.2014.06.011.
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